Making CAR-T Responses Last

A new approach to durable cell therapy

Koi Biotherapeutics is developing CAR-Enhancers (CAR-Es), a new class of biologics designed to improve the persistence and durability of CAR-T therapies.

Explore Our Science →

CAR-T has transformed cancer treatment.But for many patients, responses don’t last.

~50%

of patients treated with CD19 CAR-T relapse within the first year

CD19 CAR-T (Expert Rev Clin Immunol, 2024)

~45–70%

of BCMA CAR-T patients experience disease progression or death within 2–3 years.

Carvykti (J Clin Oncol, 2023) · Abecma (N Engl J Med, 2023)

Limited CAR-T persistence and inadequate formation of long-lived functional memory are key barriers to durable responses.

Introducing CAR-Enhancer (CAR-E)

Designed to make CAR-T responses last longer.

CAR-E is a protein therapeutic administered after CAR-T infusion, designed to enhance CAR-T expansion, persistence, and long-term functional memory.

CAR-E mechanism bringing CAR and IL-2Rβγ into close proximity on a CAR-T cell

Novel Biology

Brings CAR and IL-2 receptor signaling into close proximity, creating synergy that enhances CAR-T activity, persistence, and the generation of a memory-like phenotype.

Targeted Activity

Selectively activates CAR-T cells without detectable activation of other immune cells.

Broad Compatibility

Administered after CAR-T infusion without re-engineering CAR-T cells or changing their manufacturing process.

OUR LEAD PROGRAM

Advancing BCMA CAR-E toward the clinic

Multiple Myeloma | IND-Enabling Development

Our lead program is developing BCMA CAR-E as an add-on therapy following BCMA-directed CAR-T treatment, with the goal of improving CAR-T persistence and durability of response.

Preclinical studies have demonstrated enhanced CAR-T activity, persistence, and long-term functional memory, supporting continued development toward clinical evaluation.

Nature Biotechnology (July 2024)

Published research

↗

JITC (Feb 2026)

Published research

↗

Preclinical Validation

IND-Enabling Development

Current Stage

Clinical Evaluation

BROADER APPLICATIONS

Expanding the potential of cell therapy

Beyond our lead BCMA CAR-T program, encouraging results from preclinical mouse studies support the potential of Koi's Enhancer across additional cell therapy modalities.